In FCS, mutations in the lipoprotein lipase gene lead to an accumulation of chylomicrons in plasma resulting in severe hypertriglyceridemia.

An FDA approval later this year for Arrowhead’s plozasiran in FCS would put it in direct competition with Ionis’ Tryngolza.

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the U.S. Food and Drug Administration (FDA) has accepted ...

ManaMed LLC, a global leader in orthopedic mobility and post-operative rehabilitation equipment, is thrilled to announce the launch of three groundbreaking products designed to enhance patient care.

Arrowhead Pharmaceuticals said Friday that the Food and Drug Administration accepted the company's new drug application for its treatment of familial chylomicronemia syndrome, a severe and rare ...

Pharmaceuticals announced that the U.S. FDA has accepted the New Drug Application for investigational plozasiran for the ...

Arrowhead Pharmaceuticals announces FDA acceptance of NDA for plozasiran to treat familial chylomicronemia syndrome, with a target action date of Nov.

In 2024, there were numerous trials and a few regulatory moves related to advancements in lipid management for the prevention ...

As the year unfolds the biotech industry will look closely at these ten first-in-class drugs on track to reach FDA approval ...

"I'm a physician and I thought there could be a better way to detect the presence of a carotid pulse during the pulse check pause when resuscitating cardiac arrest patients," said one of two inventors ...

CEO Christopher Richard Anzalone sold 11,520 shares of the stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $19.05, for a total value of ...